NCIt related terms : Bevacizumab IFL; FOLFIRI and Bevacizumab (L-Leucovorin); FOLFIRI and Bevacizumab; FOLFIRI and Bevacizumab-awwb; FOLFIRI and Bevacizumab-equi (L-Leucovorin); FOLFIRI and Bevacizumab-aybi; FOLFIRI and Bevacizumab-bvzr; FOLFIRI and Bevacizumab-maly (L-Leucovorin); FOLFIRI and Bevacizumab-adcd (L-Leucovorin); FOLFIRI and Bevacizumab-equi; FOLFIRI and Bevacizumab-adcd; FOLFIRI and Bevacizumab-onbe (L-Leucovorin); FOLFIRI and Bevacizumab-aybi (L-Leucovorin); FOLFIRI and Bevacizumab-awwb (L-Leucovorin); FOLFIRI and Bevacizumab-onbe; FOLFIRI and Bevacizumab-maly; FOLFIRI and Bevacizumab-bvzr (L-Leucovorin);
NCIt definition : A regimen consisting of bevacizumab, fluorouracil, irinotecan and leucovorin that
may be used in the treatment of ampullary and appendiceal adenocarcinoma, colorectal
cancer, and small bowel adenocarcinoma.;
Alternative definition : NCI-GLOSS: A chemotherapy combination used as an initial treatment of colorectal cancer
that has spread. It includes the drugs leucovorin (folinic acid), fluorouracil, irinotecan
hydrochloride, and bevacizumab.;